- Walgreens is exploring a sale to Sycamore Partners to take the company private. The deal could be finalized in early 2025.
- Once valued at over $100B, Walgreens’ market cap has plunged to $7.5B due to mounting challenges in its pharmacy and retail businesses.
- If successful, the acquisition would likely involve restructuring, with Sycamore potentially divesting parts of the business.
Walgreens (WBA), one of the world’s largest retail pharmacy chains, is in talks with private equity firm Sycamore Partners to take the company private.
If finalized, the deal could mark a significant shift for Walgreens, potentially taking the 12K-store chain off the public market and paving the way for a major restructuring, as reported by the WSJ.
The Decline of Walgreens
The potential privatization comes after years of declining performance, with the company’s market value dropping from a peak of over $100B in 2015 to just $7.5B today.
Walgreens, a household name in retail pharmacy, operates over 12K stores across the US, Latin America, and Europe. However, the retailer’s fortunes have waned, with shares down nearly 70% in 2024. Despite efforts to diversify, including investments in healthcare clinics, Walgreens has struggled under pressures from shrinking pharmacy margins and competition from e-commerce giants like Amazon (AMZN).
Its financial challenges stem from its 2015 acquisition of Alliance Boots, a $6B deal intended to expand its international presence. While the merger initially appeared promising, it proved rocky and has since prompted consideration of divesting the Boots chain.
The Potential Buyer
Sycamore Partners, a New York-based private equity firm specializing in retail and consumer investments, is leading the acquisition talks. Known for deals involving Staples, Hot Topic, and Ann Taylor, Sycamore has a history of restructuring retail brands. If a deal is finalized, Sycamore is expected to sell off portions of Walgreens or collaborate with partners to manage its assets.
The potential sale underscores a broader trend of private equity firms targeting struggling retailers, albeit cautiously. Walgreens’ diminished market value makes it a more feasible acquisition than past attempts, such as KKR’s failed $70B bid in 2019.
Get Smarter about what matters in CRE
Stay ahead of trends in commercial real estate with CRE Daily – the free newsletter delivering everything you need to start your day in just 5-minutes
Subscribe
Pharmacy Challenges
Walgreens faces industry-wide headwinds, including pressure from pharmacy-benefit managers who negotiate drug prices and razor-thin margins in retail operations. Unlike its competitor, CVS Health (CVS), which diversified into insurance and pharmacy-benefit management, Walgreens has remained focused on its retail pharmacy model.
Under CEO Tim Wentworth, who joined in October 2023, Walgreens has initiated cost-cutting measures, including store closures and scaling back its primary-care ventures. The company is set to report quarterly earnings on January 9, which could influence the direction of the talks.
Implications of the Sale
A private equity acquisition could provide Walgreens with the financial support to restructure and refocus its business. However, such deals often come with significant operational changes, including potential layoffs, asset sales, and shifts in strategy.
If Sycamore Partners succeeds, the deal will cap a dramatic chapter in Walgreens’ history, reflecting both the challenges of the retail pharmacy industry and the ongoing appeal of restructuring opportunities for private equity investors.
